Clinical Trials Directory

Trials / Terminated

TerminatedNCT01535937

The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
55 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This project will evaluate the effect of a single sub-anesthetic dose of ketamine on the time to first cocaine use and abstinence rates in 60 treatment-seeking cocaine-dependent individuals receiving mindfulness-based relapse prevention (MBRP) therapy, using a 5 week combined laboratory-inpatient and outpatient double-blind, randomized, controlled trial.

Detailed description

he study will begin with an inpatient phase (phase 1) of 5 days, during which abstinence is achieved, followed by a 4 week outpatient phase (phase 2). A single infusion of ketamine or midazolam will occur on day 3 of Phase 1. In addition to measures of mindfulness and impulsivity, stress sensitivity tests are incorporated into the design in order to elucidate mechanisms of action. The study hypotheses are: 1. ketamine and MBRP will significantly increase the time to first use compared to placebo and MBRP in cocaine-dependent individuals. 2. ketamine and MBRP is significantly more likely to lead to abstinence from cocaine (no use over one week) as compared to placebo and MBRP. 3. ketamine and MBRP will significantly reduce subjective, endocrine, and physiological responses to stress (including cue exposure) as compared to placebo and MBRP. 4. ketamine and MBRP will significantly increase mindfulness, as assessed by the Five Facet Mindfulness Questionnaire (FFMQ), as compared to placebo and MBRP.

Conditions

Interventions

TypeNameDescription
DRUGKetamine0.5 mg/kg IV over 40 minutes
DRUGMidazolam0.025 mg/kg IV over 40 minutes

Timeline

Start date
2012-02-01
Primary completion
2017-01-01
Completion
2017-04-01
First posted
2012-02-20
Last updated
2019-05-01
Results posted
2018-09-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01535937. Inclusion in this directory is not an endorsement.